±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾

English

¹ú²ú¿¹XaÖÊÁ¿ÔõÑù£¿¶àÖÐÐÄÁÙ´²Ñо¿À´¸æËßÄ㣡

Ðû²¼ÓÚ£º2023-09-20

ÎÄÕÂȪԴ£º[ÖÐÎÄ]±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎï



Ç°ÑÔ


ÏÖÔÚ£¬¾²ÂöѪ˨˨ÈûÐÔ¼²²¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÉú³ÝéæÃüµÄµÚһλԵ¹ÊÔ­ÓÉ¡£´ó´ó¶¼¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕµ«VTEÊÇ¿ÉÒÔÔ¤·ÀµÄ£¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÖÎÁƵĻù´¡¡£¿ÉÊÇÔõÑù×èÖ¹¿¹ÄýÖÎÁƵ¼ÖµijöѪÐÔΣº¦£¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¹ØÓÚ²î±ð¿¹ÄýÒ©Îï¸ø³öÁËÏà¹ØµÄ¼à²âÖ¸±ê¡£


  • ÈôÓ¦ÓÃUFHÖÎÁÆ£¬ÍƼöÒ»Á¬¾²Âö¸øÒ©²¢Æ¾Ö¤»î»¯²¿·ÖÄýѪøԭʱ¼ä£¨APTT£©¼à²âЧ¹ûµ÷Àí¼ÁÁ¿£¬Ö±ÖÁAPTTÑÓÉìÖÁ¿¹ÄýÇ°µÄ1.5~2.5±¶£¬»òµÖ´ïÏ൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÖÎÁƶøAPTT²»´ï±êʱ£¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽָµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿¡£

  • Ó¦ÓÃLMWHÖÎÁƼ±ÐÔDVTʱ£¬ÈôºÏ²¢ÑÏÖØÉö¹¦Ð§²»È«£¨¼¡ôûɨ³ýÂÊ<30 ml/minʱ£¬É÷ÓÃLMWH£©£¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿¡£


¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËصÄÖÎÁƹæÄ£Ò²¸ø³öÁ˽¨Ò飺ÈÑÉïʱ´úÐè°´ÆÚ¼à²â¿¹Xa»îÐÔ£¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨£¬¹ÈÖµÓ¦ÔÚÏ´Î×¢ÉäÇ°²â¶¨£¬¿¹Xa»îÐÔÄ¿µÄ¹æģΪ0.6¡«1.0 IU£¯ml£¬ÌìÌì¸øÒ©1´ÎµÄÄ¿µÄ¹æģΪ1.0¡«2.0 IU£¯ml¡£


Ðí¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð±ê×¼²âÊÔ£¬ÒÔ¼à²âºÍµ÷½âÖÎÁÆÐÔδ·Ö×é¸ÎËغ͵ͷÖ×Ó¸ÎËØÖÎÁƵĹÜÀí¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇÏÖÔÚ¼à²âµÍ·Ö×Ó¸ÎËØÖÎÁƵĽð±ê×¼¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·


ʹÓÃUFHºÍLMWH¾ÙÐп¹ÄýÖÎÁÆʱ£¬ÏÂÁÐÈËȺÐèÒª¾ÙÐмà²â£º


  • Ó¤Ó׶ùºÍ¶ùͯ

  • ÀÏÈË£¨ÄêËꣾ85Ë꣩

  • ÌåÖØÒì³£Õß

  • ¼¡ôûɨ³ýÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

  • ÈÑÉ︾Ů

  • ÓгöѪΣº¦µÄ»¼ÕßµÈ


¿¹Xa»îÐÔ¼ì²â


¼ì²âÔ­ÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪøÍŽáÐγɸ´ºÏÎïºó£¬»áÓ벿·ÖXa͎ᣬ²¢Ê¹Õⲿ·ÖXaʧ»î¡£Ê£ÓàµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×ÎïÆÊÎö±¬·¢¶ÔÏõ»ù±½°·£¨PNA£©£¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊշ壬ͨ¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÅÌËã¸ÎËØ»îÐÔ¡£


¿¹Xa»îÐÔ¼ì²âÔ­Àíͼ


ÊÔ¼ÁÐÔÄÜ


±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÑÕɫת±äÀ´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È£¬ÏßÐÔ¿í£¬¿¹×ÌÈÅÄÜÁ¦Ç¿£¬Ï¸Ãܶȸߣ¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÏà¹ØÐÔÓÅÒ죬R2£¾0.95£¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó¡£


£¨Êý¾ÝȪԴ£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


½ð˹¶û¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º

½ð˹¶û¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL£¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó¡£

¿¹×ÌÈÅÄÜÁ¦Ç¿£º

±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾¿¹XaÊÔ¼ÁºÐ²¿·ÖÖ¸±ê£¬¿¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£


С½á

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWHµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨¡£


4¼ÒÈý¼×Ò½ÔºÅäºÏ¼ÓÈëÁËÖйúÑо¿ÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿ÐÔÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌ⣬¾­¶àÖÐÐÄʵÑéЧ¹ûÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ±ÈÕÕÊÔ¼ÁµÄ²âÖµµÄÏà¹ØÐÔÓÅÒ죺ÎÞÂÛÊÇͨË׸ÎËØÕվɵͷÖ×Ó¸ÎËØ£¬²âÖµÏà¹ØÐÔ¾ùÔÚR2£¾0.95£¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇó£»

£¨2£©¹ú²ú¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL£¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇó£»

£¨3£©¹ú²ú¿¹XaÊÔ¼ÁÐÔÄÜÆÀ¼ÛÓÅÒ죬ΪÁÙ´²Ìṩ¹ú²úÌæ»»µÄÑ¡Ôñ£ºÐÔÄÜÆÀ¼ÛÊý¾ÝÏÔʾ£¬±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾¿¹XaÊÔ¼ÁºÐµÄ¸÷ÏîÐÔÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ã棬¶ÔÖ±½Óµ¨ºìËغÍѪºìÂѰ׵Ŀ¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£





¡¶¿¹Xa¶àÖÐÐÄЧ¹û»ã±¨ÓëÆÊÎö¡·

ԢĿͨµÀ

¢Ù PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýѪÔÆ¿ÎÌÃƽ̨£¬Ô¢Ä¿ÊÓƵ£º

https://vfs.xet.tech/s/2YYnDS

¢Ú H5¶Ëʶ±ðÏ·½¶þάÂ룬¼´¿ÉÌøתÖÁÊÓƵҳÃ棺



±¦ÔËÀ³¹Ù·½ÓéÀÖÍøվѪÄý¼ì²âϵͳ


±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎïÊÇÖйúÁìÏȵÄÁÙ´²ÌåÍâÕï¶Ï²úÆ·Óë·þÎñ¹©Ó¦ÉÌÖ®Ò»£¬ÏÖÔÚÓµÓÐ×ÔÖ÷Ñз¢µÄÈ«×Ô¶¯ÄýѪ¼ì²âÆÊÎöÒÇMDC7500ºÍMDC3500ÒÔ¼°µÂ¹úÔ­×°Èë¿ÚµÄCoatron5000¡¢Coatron3000ºÍCoatron1800£¬×¨ÒµÅäÌ×µÄÄýѪ¼ì²âÊÔ¼ÁÔÚÖª×ã×ÔÓмì²âϵͳµÄͬʱҲÄÜÍêÉÆÆ¥ÅäÖ÷Á÷ѪÄý¼ì²âϵͳ£¬Öª×ã²î±ð¿Í»§µÄÐèÇó£¬ÎªÁÙ´²ÌṩÖÜÈ«µÄѪ˨ÓëֹѪʵÑéÊÒ½â¾ö¼Æ»®¡£





²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áÒâѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÓ¦ÓÃ[J].±ê¼ÇÃâÒßÆÊÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄʵÑéÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨË׸ÎËØ¿¹Äý¼à²âÖÐÓ¦ÓõÄÑо¿Ï£Íû[J].ÖйúÌåÍâÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

ÉÏÏ»¬¶¯Éó²éÍêÕû²Î¿¼ÎÄÏ×



END

ÎÄÕÂȪԴ£º±¦ÔËÀ³¹Ù·½ÓéÀÖÍøÕ¾ÉúÎï

Ôð±à£ºEcho

У¶Ô£ºÐ¡¾Å¡¢Cassie


 
ÍøÕ¾µØͼ